Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

110.05 +0.81 (+0.75%)
Streaming Delayed Price Updated: 9:55 AM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glaukos Corporation Common Stock

< Previous 1 2 3 4 Next >
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Third Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Approval of Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2024 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
From Glaukos Corporation
Via Business Wire
News headline image
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Third Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.